Cowen Downgrades Life Technologies Amid Acquisition Chatter | GenomeWeb

NEW YORK (GenomeWeb News) – Citing a recent run up in Life Technologies' stock fueled by speculation that it may be positioning itself to be bought, investment bank Cowen & Co. today downgraded the Carlsbad, Calif.-based firm to Neutral from Outperform.

Analyst Doug Schenkel added in a research note that amid reports that several potential buyers may be preparing to bid on Life Tech, "[w]e do believe there is a transaction to be done (at the right price)."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.